CCR2 and neoplasm: The results demonstrated that the triple-combination immunotherapy of CCR2/5i + αPD-1 + GVAX slowed the rate of tumor growth significantly compared with the control (no treatment) group, and that the addition of SBRT further significantly enhanced the antitumor effect of the triple immunotherapy regimen (Fig. 2 A).